普米克令舒联合万托林、爱全乐雾化吸入治疗COPD的成本-效果分析  

Cost-effectiveness analysis of Ventolin,Atrovent combined with Pulmicort respules on chronic obstructive pulmonary disease(COPD)

作　　者：叶放波[1] 张玉娥[1] 林女群[2] 

机构地区：[1]广东江门市五邑中医院/暨南大学医学院第六附属医院,江门529000 [2]广州中医药大学,2003级中药学本科广州510006

出　　处：《海峡药学》2008年第9期113-115,共3页Strait Pharmaceutical Journal

基　　金：2007年江门市第三批科技计划项目;编号:03

摘　　要：目的评价普米克令舒联合万托林、爱全乐雾化吸入治疗COPD的成本-效果分析。方法将90例病人随机分为两组。治疗组:60例,给予普米克令舒联合万托林、爱全乐雾化吸入;对照组:30例,给予0.9%生理盐水,万托林、爱全乐联合雾化吸入。两组在综合疗法基础上进行。观察两组症状和临床疗效,并运用药物经济学方法成本、效果方法进行比较。结果治疗组的有效率为88.33%,对照组的有效率为80.00%,两种方案单位效果所需成本治疗组为765和对照组为1042,在对照组的基础上,增加单位效果的成本是18.92。结论药物经济分析结果为普米克令舒联合万托林、爱全乐雾化吸入优于0.9%生理盐水、万托林、爱全乐联合雾化吸入。OBJECTIVE To evaluate the ratio of cost-effectiveness of atomized inhalation of ventolin, atrovent combined with pulmicort respules on chronic obstructive pulmonary disease. METHODS Ninety patients with bronchial asthma were randomly divided into two groups. Treatment group： 60 cases with atomized inhalation of ventolin, atrovent combined with pulmicort respules; comparison group：30 cases with atomized inhalation of 0.9 % sodium chloride, ventolin combined with atrovent. Integrative treatment measure were performed and symptom and clinical efficacy were observed in both groups, and pharmacoeconomic analysis was carried out. RESULTS Clinical total effective rate in treatment group were 88.33 %, in control group were 80.00 %. And cost-effectiveness rations were 765 and 1042 respectively. The ΔC/ΔE was 18.92. CONCLUSION Pharmacoeconomic analysis indicated that atomized inhalation of ventolin, atrovent combined with pulmicort respules was superior to atomized inhalation of 0.9 % sodium chloride, ventolin combined with atrovent.

关 键 词：普束克令舒 万托林 爱全乐 慢性阻塞性肺病 成本-效果分析 

分 类 号：F404.7[经济管理—产业经济]